Grant: CIHR Fellowship
Direct Payment
$150,000.00
Identification and Characterization of Novel Type VI Secretion Effectors
FY 2012-13
Summary
Pseudomonas aeruginosa is a bacterial pathogen that is the leading cause of mortality among cystic fibrosis (CF) patients. Early in their lives, the lungs of CF patients are colonized by many different species of bacteria but in almost all instances, infection by P. aeruginosa predominates as the infection persists. Many strains of P. aeruginosa are resistant to multiple antibiotics resulting in its designation as a so-called 'super bug'. In 2000, the Center for Disease Control estimated that antibiotic resistant infections cost the United States healthcare system over $20 billion a year; by extrapolation, that indicates that they cost the Canadian system more $2 billion per year. One strategy for developing antibiotic drugs is to target the cellular processes in the bacterium that it uses to infect humans rather than the viability of the bacterium itself. The idea behind this proposal is that by targeting non-essential processes, the pressure to select for antibiotic resistance will be reduced. More specifically, my proposed research concerns the type VI secretion system (T6SS) of P. aeruginosa. The T6SS is a molecular machine capable of killing other species of bacteria as well as the cells of the human host. In P. aeruginosa, this machine gives a competitive advantage to the bacterium during infection when it is competing with other bacteria for the nutrient rich tissue of the patient. P. aeruginosa strains which are missing a T6SS are at a significant competitive disadvantage in a laboratory model of human lung infection. My proposed research is aimed at better understanding the structure and function of the T6SS system, which in the future should facilitate the development of novel drugs that target this pathway and prevent P. aeruginosa from colonizing the lungs of CF patients while at the same time minimizing the emergence of antibiotic resistance.
Department
Program
CIHR Fellowship
Recipient
Location
Washington, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
280767
Name
Whitney John
Region
Washington
Country
United States of America
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Identification and Characterization of Novel Type VI Secretion Effectors
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Bacterial Fitness Competition Assays; Bacterial Pathogenesis; Cystic Fibrosis; Mass Spectrometry; Microbial Infections; Pseudomonas Aeruginosa; Toxin Secretion; Type Vi Secretion; Virulence Factors; X-Ray Crystallography
Abstract
Pseudomonas aeruginosa is a bacterial pathogen that is the leading cause of mortality among cystic fibrosis (CF) patients. Early in their lives, the lungs of CF patients are colonized by many different species of bacteria but in almost all instances, infection by P. aeruginosa predominates as the infection persists. Many strains of P. aeruginosa are resistant to multiple antibiotics resulting in its designation as a so-called 'super bug'. In 2000, the Center for Disease Control estimated that antibiotic resistant infections cost the United States healthcare system over $20 billion a year; by extrapolation, that indicates that they cost the Canadian system more $2 billion per year. One strategy for developing antibiotic drugs is to target the cellular processes in the bacterium that it uses to infect humans rather than the viability of the bacterium itself. The idea behind this proposal is that by targeting non-essential processes, the pressure to select for antibiotic resistance will be reduced. More specifically, my proposed research concerns the type VI secretion system (T6SS) of P. aeruginosa. The T6SS is a molecular machine capable of killing other species of bacteria as well as the cells of the human host. In P. aeruginosa, this machine gives a competitive advantage to the bacterium during infection when it is competing with other bacteria for the nutrient rich tissue of the patient. P. aeruginosa strains which are missing a T6SS are at a significant competitive disadvantage in a laboratory model of human lung infection. My proposed research is aimed at better understanding the structure and function of the T6SS system, which in the future should facilitate the development of novel drugs that target this pathway and prevent P. aeruginosa from colonizing the lungs of CF patients while at the same time minimizing the emergence of antibiotic resistance.
Competitiondate
201302
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Whitney, John
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~